Pharma Pulse 3/18/25: Causes of the Innovation Gap in Women’s Health, FDA Grants Kerendia Priority Review in Heart Failure & more

The Root Causes of the Innovation Gap in Women’s Health

In this Pharmaceutical Executive video interview, Dr. Dina Radenkovic, CEO of Gameto, discusses the company's pioneering use of induced pluripotent stem cell (iPSC) technology in fertility treatments, particularly addressing ovarian aging. Its lead product, Fertilo, is an iPSC-derived ovarian support cell line in phase III clinical trials in the US with FDA clearance, and commercial availability in markets like Australia and Latin America. The company faces challenges including the scarcity of human eggs and regulatory hurdles. Radenkovic also highlights the need for better models to study female-specific conditions and the importance of political advocacy and funding to drive innovation in women's health.

FDA Grants Priority Review to Kerendia in Heart Failure

Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with a left ventricular ejection fraction (LVEF) of ≥40%.

Novo Reinstated by UK Pharma Body After Two-Year Suspension

Novo Nordisk A/S is a member of the UK pharmaceutical industry association again, following a two-year suspension for breaching the country’s code of practice for drugmakers.

GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

GoodRx has announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately.

@pharmexecutive on Threads

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs